The numbers tell a blunt story. External financing for health in Africa contracted by roughly 70% between 2021 and 2025. The US dissolved USAID, forcing Nigeria to absorb 28,000 health workers at a cost of $200 million. Ghana lost $78 million in maternal healthcare, malaria treatment, and HIV/AIDS programs overnight. South Africa's PEPFAR funding — over $400 million annually, credited with saving 26 million lives since 2003 — was pulled, leaving 1.4 million people living with HIV facing treatment uncertainty. Clinics closed. The damage, researchers told the International AIDS Conference in Brazil, has been "severe and devastating." The Accra Reset, a global health initiative led by Ghanaian President John Dramani Mahama, published its report "A Sovereign Future For Health" on Monday. Its core argument is not that the US should restore aid — though it doesn't argue against that either. The argument is structural: a continent that produces less than 1% of its own vaccines while carrying 25% of the global disease burden was always one policy change away from crisis. The Trump administration's cuts simply proved it. Mahama frames the past few years as a triple shock: COVID-19 exposed concentrated production and unequal access; rising debt constrained national health budgets; and declining development assistance placed programs under growing strain. These are not separate crises. They are the same fragility expressed through different channels. A system dependent on external financing for essential services is not a system — it is a permission structure that can be revoked. The report's proposed remedy is sovereignty over health systems, not isolation from the global order. The Rockefeller Foundation's Naveen Rao explicitly stated this is "not an argument for traditional donors to do less" but "for doing it differently." The vision: African countries set priorities, donor countries follow their lead rather than dictating terms. Whether this is genuinely achievable or aspirational framing for a negotiating position remains to be seen. Notably, the report arrives alongside Rockefeller Foundation-commissioned polling of 2,000 US adults showing 75% support restoring disease-prevention aid to contain Ebola — including 52% of primarily Trump-supporting respondents. Some 65% support international cooperation even at cost to national interests. The gap between US public opinion and US policy is wide enough to drive a truck through. The extraction mechanics here run in multiple directions. The US withdrawal extracts health security from African populations who had no vote in the decision. But the prior arrangement was itself extractive in a subtler way: decades of donor dependency channeled health governance through Washington's priorities rather than Accra's or Abuja's. The Accra Reset is essentially arguing that the violent end of one extraction regime creates an opening to avoid building the next one. The 20-year question is whether African states can actually build domestic pharmaceutical capacity, vaccine manufacturing, and health financing at scale — or whether the sovereignty framing becomes a fig leaf for chronic underfunding. Africa producing less than 1% of its vaccines is not a stat that moves quickly. The structural gap between aspiration and industrial capacity is enormous, and the report is more politically forceful than technically specific about how to close it.
